12:13 PM EDT, 05/02/2024 (MT Newswires) -- Genmab ( GMAB ) reported interim Q1 diluted earnings Thursday of 20.18 Danish kroner ($2.90), up from 3.19 Danish kroner a year earlier.
Analysts polled by Capital IQ expected 12.80 Danish kroner.
Revenue for the quarter ended March 31 was 4.14 billion Danish kroner, up from 2.83 billion Danish kroner a year earlier.
Analysts polled by Capital IQ expected 3.99 billion Danish kroner.
The company said it is maintaining its 2024 revenue guidance of 18.70 billion to 20.50 billion Danish kroner. Analysts surveyed by Capital IQ expect 19.67 billion Danish kroner.
Genmab ( GMAB ) shares fell more than 3% in recent trading activity.
Price: 27.74, Change: -1.01, Percent Change: -3.51